{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"0.640","floor":"0.440"},"ipodate":{"start":"2018-11-30 00:00:00","end":"2018-12-05 00:00:00"},"minimumcapital":"5171.60","subscribed":"131.52","marketcap":"2.00億","H_marketcap":"--","pe":"--","codesrate":"15.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/08622/GLN20181129010_C.pdf","ipopricing":"0.500","resultdate":"2018-12-12 00:00:00","enddate":"2018-12-05 00:00:00","listeddate":"2018-12-13 00:00:00","issuenumber":"10000.00萬","issuenumberhK":"5000.00萬","issuenumberother":"5000.00萬","grayprice":"0.51","sponsors":"興業金融融資有限公司","raisemoney":"1660.00萬","use":"1、所得款項凈額41.5%（或6.9百萬港元）將用于開發新產品、改良我們的現有產品及開展國際合作項目；\n2、所得款項凈額27.3%（或4.5百萬港元）將用于擴展我們的銷售網絡以及加強我們的銷售及營銷活動；\n3、所得款項凈額27.9%（或4.6百萬港元）將用于發展輔助生育用品業務；\n4、所得款項凈額3.3%（或548,000港元）將用于為營運資金撥付資金。","shares":8000,"leadagent":"利得證券(香港)有限公司,力高證券有限公司,勤豐證券有限公司","bookrunners":"利得證券(香港)有限公司,長雄證券有限公司","coordinator":"","firstDayOpen":"0.50","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"--","StabilizingManager":"--","code":"E08622","name":"華康生物醫學","fullname":"華康生物醫學控股有限公司"},"institutioninfo":{"principaloffice":"中國深圳市大鵬新區葵涌街道葵新小區銀葵路16號深圳君軒D棟一至三層","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333","chairman":"張曙光","secretary":"周麗麒","telephone":"(0755)3283 3299","substantialshareholders":"Crystal Grant(36.14%),Ever Charming(23.86%),Gallizul(9%),","principalactivities":"公司是一家專注于在中國研發、生產及銷售各種體外診斷試劑的醫療器械集團。","website":"http://www.szhuakang.com"},"managerinfo":[{"managername":"張曙光","post":"主席兼執行董事","rankno":1},{"managername":"張春光","post":"行政總裁兼執行董事","rankno":2},{"managername":"潘禮賢","post":"首席財務官兼執行董事","rankno":3}],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":507}